Maxim Group Issues Negative Outlook for Scienture Earnings

Scienture Holdings, Inc. (NASDAQ:SCNX) – Research analysts at Maxim Group cut their Q3 2026 earnings estimates for shares of Scienture in a note issued to investors on Thursday, October 29th. Maxim Group analyst N. Rahman now anticipates that the company will earn ($1.57) per share for the quarter, down from their prior estimate of ($1.50). Maxim Group currently has a “Buy” rating and a $6.00 target price on the stock. The consensus estimate for Scienture’s current full-year earnings is ($5.75) per share. Maxim Group also issued estimates for Scienture’s Q4 2026 earnings at ($0.37) EPS, FY2026 earnings at ($4.44) EPS and FY2027 earnings at ($0.27) EPS.

Other analysts also recently issued research reports about the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Scienture in a research note on Monday, September 21st. Zacks Research raised Scienture to a “hold” rating in a research note on Friday, October 2nd. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Scienture presently has a consensus rating of “Hold” and an average target price of $6.00.

Scienture Stock Up 0.3%

Shares of NASDAQ SCNX opened at $3.23 on Tuesday. The stock has a fifty day moving average price of $6.17 and a two-hundred day moving average price of $9.17. The company has a quick ratio of 2.97, a current ratio of 3.04 and a debt-to-equity ratio of 0.15. Scienture has a 1 year low of $2.64 and a 1 year high of $27.75.

Scienture (NASDAQ:SCNX) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($0.07) EPS for the quarter, beating analysts’ consensus estimates of ($2.25) by $2.18. The company had revenue of $0.34 million for the quarter, compared to analyst estimates of $1.96 million.

Institutional Inflows and Outflows

A hedge fund recently bought a new position in Scienture stock. Susquehanna International Group LLP bought a new position in Scienture Holdings, Inc. (NASDAQ:SCNX) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 235,117 shares of the company’s stock, valued at approximately $82,000. Susquehanna International Group LLP owned about 0.57% of Scienture as of its most recent SEC filing. Institutional investors and hedge funds own 5.68% of the company’s stock.

About Scienture

Scienture Holdings, Inc is a specialty pharmaceutical company focused on developing and commercializing medicines for central nervous system disorders. The company seeks to address unmet treatment needs through pharmaceutical products and drug-delivery technologies designed to improve patient convenience and therapeutic use.

Scienture’s areas of interest include conditions such as insomnia, attention-deficit/hyperactivity disorder, anxiety, depression and pain. Its portfolio includes product candidates and commercial opportunities involving alternative delivery formats, including oral formulations and sprays.

The company serves the pharmaceutical market primarily in the United States.